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A B ST R AC T 
 
 
Rosacea is a chronic inflammatory skin disease with a complex 
pathogenesis that mainly affects the central part of the face, with a global 
incidence of 5.46%. The present study was performed on a group of 68 
patients with rosacea 1 and 2 subtypes, patients between 34-63 years old. 
The treatments were performed using a Cutera Xeo laser, using 2 types of 
probes: NdYag 1064nm for telangiectasias and LimeLight 520-1100nm for 
diffuse facial erythema, papules, and pustules, having an 10x30mm 
window. For patients with diffuse facial erythema, etc., the optimal number 
of sessions was between 3 and 6 with or without anesthetic cream, using 
energies between 14-19J / cm. The average recovery time was 5 days. 
Registered effects included bruises, pustules, burning sensation, transient 
stinging, and hypopigmentation. For patients with telangiectasia, the 
optimal number of sessions was two, performed at an average interval of 
once per month/ monthly.   
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Introduction  
Rosacea is a chronic inflammatory disease of the skin 
with a complex pathogenesis that mainly affects the central 
part of the face [1]. The term “rosacea” was introduced in 
the 19th century by Thomas Bateman [2]. The disease 
affects both sexes and can be found at any age, but 
frequently, the debut of the disease occurs after the age of 
30 years.  
In women, there was an increased incidence of 
erythematotelangiectatic and papulopustular rosacea, in 
which the debut was recorded after the age of 40 [3]. The 
incidence of the disease according to the latest reported 
statistical data is between 0.09 and 22.41%, with an 
average of 5.46% amongst world populations [4;5], 
reaching up to 10% among the Caucasian population [6]. 
The disease is also more common for Fitzpatrick III and IV 
phototypes, and lower for V and VI phototypes [6]. From 
a clinical point of view, the disease is manifested by facial 
erythema (transient or persistent), telangiectasia, edema, 
papules and pustules, burning sensation, stinging, pain or 
itching; patients may show one or more signs and 
symptoms [7]. There are also cases in which patients are 
completely asymptomatic, the disease having only facial 
skin signs [8]. The disease has a sinusoidal evolution, with 
periods of remission and exacerbation. It is important to 
emphasize the role of Demodex Folliculorum in the 
appearance of Rosacea, because its number is increased in 
confirmed patients compared to patients without rosacea, 
questioning whether its multiplication directly or indirectly 
produces rosacea, or alternatively whether rosacea is 
favorable ground for its multiplication. Studies show that 
Demodex Folliculorum can be present and multiplied 
without producing rosacea, only spinulosis, including areas 
other than the central facial area. Sometimes its presence 
and associated endosymbiont bacteria, described in the 
literature, can produce rosacea or demodeciosis with 
inflammatory elements, objectified through spectrometric 
bacteriological methods, imagistic- ex: VISIA dermoscopy 
[9-12]. 
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Rosacea was classified into 4 main subtypes: 
erythemothelothelectectic (subtype 1), papulopustular 
(subtype 2), phytomatous (subtype 3), and ocular (subtype 
4), granulomatous rosacea being considered a variant/type 
of rosacea rather than a subtype. Since 2017, the 
classification of rosacea is based on phenotypes and for the 
diagnosis of rosacea, at least one diagnosis or two major 
phenotypes are required [6].  
The diagnostic phenotypes for rosacea are:  
• Persistent erythema of the central face area that 
worsens with some triggers  
• Phytomatic changes (most commonly rhinophyma)  
The major phenotypes for rosacea are:  
• Transient facial erythema of the central face  
• Inflammatory papules and pustules  
• Telangiectasias  
• Ocular changes: blepharitis, keratitis, conjunctivitis, 
ocular telangiectasias  
Minor phenotypes for rosacea are:  
• Burning sensation  
• Stings  
• Edema  
• Dryness [13].  
Also, a particular type of rosacea is the secondary one, 
induced by the prolonged use of cutaneous 
dermatocorticoids or calcineurin inhibitors [14-17]. 
Materials and Methods 
The present study is based on 68 patients, with the age 
between 34-63 years with a prevalence of women (76%). 
The inclusion criteria were: patients with rosacea subtypes 
1 and 2. Exclusion criteria were: patients with rosacea 
subtypes 3 and 4. 
The treatments were performed with the Cutera Xeo 
laser, using 2 probes: NdYag 1064 nm and LimeLight 520-
1100 nm, with a 10x30 mm window. The protocol used in 
the study was: 
− for telangiectasia (cuperosic stage of the disease), 
NdYag treatment was applied, 1 session every 1-2 
months. The working parameters   were: 3 mm spot, 
time 15-25 ms, energy 110-130 J / cm2. 
− for diffuse facial erythema, papules, and pustules, the 
LimeLight probe was applied, 1 session of 3-4 weeks, 
program A (vascular) and an energy of 15-19 J / cm2. 
Since the two conditions usually exist simultaneously, 
the following steps have been followed: LimeLight 
sessions were done every 3-4 weeks, followed by the 2 
NdYag sessions. 
The treatments were performed exclusively between 
October and May of the same year. For maintenance, we 
recommend 1-2 sessions of LimeLight annually during 
winter. Post-procedure, all patients received 
recommendations to use a mixture of cream with a 
protection factor of at least 50% during the entire length of 
treatment, to avoid exposure to excessive heat such as 
sauna, sun, or solarium exposure, and to avoid alcohol 
consumption.  
Results 
For patients with diffuse facial erythema, papules, etc., 
the optimal number of sessions with the LimeLight probe 
was 4, at intervals of 3-4 weeks. The maximum number of 
sessions was 6, the fewest 3. Most treatments were 
performed without anesthetic cream though some patients 
wanted to use the cream. The degree of discomfort during 
the procedure was medium, and the treatments were started 
from energies of 14-15 J/cm2 and increased progressively, 
from session to session, to energies of 18-19 J/cm2. The 
average recovery time was 5 days, during which the patient 
presented with severe edema. As side effects, there were 
small bruises, small pustules, burning sensation, and 
transient stinging. As complications, in 3 patients there 
were observed areas of hyperpigmentation, partially 
remitted. We did not record any post-procedure scars. 
Although after the first sequence of LimeLight procedure, 
many patients said they would stop treatment, ultimately 
all patients completed the treatment. 
For patients with telangiectasia, the optimal number of 
sessions was 2, performed on average monthly. 
Telangiectasia disappeared completely after these 2 
sessions. As for complications, in two cases there were 
small excavations in the nose, instead of blood vessels, 
almost imperceptible but permanent. As an advantage, 
however, a reduction in the volume of the nose was 
observed. The area of predilection treated was that of the 
nose, followed by the chin and only in a few cases by the 
zygomatic areas. It did not require recovery time and the 
treatment was well tolerated by all patients. No local 
anesthesia was required.  
Discussions 
It is known that rosacea has negative effects on quality 
of life, including psychosocial well-being in people with 
mild, moderate, or severe erythema. However, this impact 
on self-perception and emotional, social, and general well-
being is significantly higher in people with severe 
erythema [18]. Thus, we paid special attention to 
improving the quality of life of these patients [19]. In this 
case, the end results were very positive, with an excellent 
aesthetic result and with complete remission of the 
symptoms in most cases. The degree of satisfaction of the 
patients was very good, with the return to normal of their 
self-confidence and well-being. 
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Rosacea treatment is not standardized; we are still 
seeking optimal treatment protocols. One of the usual 
therapeutic approaches for rosacea is based on reducing 
inflammation, using various drugs and substances such as 
doxycycline [20], metronidazole [21], topical azelaic acid 
[22], sodium sulfacetamide [23] and calcineurin inhibitors, 
[24], ivermectin, pimecrolimus, retinoids, permethrin, 
benzoyl peroxide, erythromycin, and dapsone [25]. 
Utilization of serine protease inhibitors is considered an 
emerging therapy for rosacea [26]. Isotretinoin has also 
been used in patients with papulopustular subtype rosacea 
[27]. But this approach is useful only in the early stages, 
with the improvement of symptoms, though with 
suboptimal aesthetic results and in most cases with a non-
negligible toxicity for the body, with gastrointestinal 
disorders or increased photosensitivity. 
Recently, photodynamic therapy (PDT) has 
increasingly gained ground [28,29], sometimes in 
association with other treatments such as methyl ester 
aminolevulinate (MAL) [30]. Furthermore, an in vitro 
study performed on mouse skin showed that the most 
effective wavelengths are 630 nm and 940 nm, which 
decrease some mediators of rosacea inflammation, such as 
cathelicidin (LL-37), TLR2 and kallikreins (KLKs) [31]. 
Photodynamic therapy also interacts with the skin 
microbiome [32]. Research is currently continuing on the 
effectiveness of blue and red light on the skin’s microflora 
in patients with rosacea and acne patients [33]. 
Different types of lasers with wavelengths between 
400-1400 nm are used to treat diffuse facial erythema. 
Thus, in addition to intensely pulsed light that involves a 
wide spectrum of wavelengths, 595 nm colored pulse lasers 
(PDL) are also used. Furthermore, the use of intensely 
pulsed light at a wavelength of 560 nm is as effective as the 
PDL laser in the treatment of facial erythema, but with 
much lower side effects than the PDL laser and with a 
shorter recovery time [32], this being the main 
consideration for using a laser with intense pulsed light and 
not a PDL. Most people who present with rosacea are 
active people who cannot afford long periods of recovery. 
[34]. 
For the treatment of telangiectasias, the range of lasers 
used is larger. However, the principle underlying their 
functioning in the case of vascular lesions is the same, 
namely the absorption of energy by hemoglobin [35]. Thus, 
the lasers used to treat telangiectasia are: 1064 nm 
Neodymium-doped, yttrium – aluminum – garnet (Nd-
YAG), 532 nm Potassium-Titanium-Phosphate (KTP), 595 
nm PDL, dual wavelength long-pulsed 775 nm alexandrite/ 
1,064 nm neodymium: yttrium-aluminum (LPAN) [36]. 
The most used lasers, however, remain by far NdYag 1064 
nm and PDL 595 nm. 
As far as the approach order of rosacea lesions, all 
authors prefer to use in the first stage intense pulsed light 
(IPL) followed by the use of NdYag or PDL lasers to close 
telangiectasia [25], an approach that we have used in our 
clinic. NdYag lasers have the advantages over PDL of less 
pain production, shorter recovery time, and fewer 
complications, yet with results that are comparatively the 
same [25], and thus, the basis for choosing the NdYag laser 
and not a PDL in the treatment of telangiectasia. The 
efficiency of NdYaG lasers can be increased by combining 
it with topical substances based on retinoic acid (some 
authors find this increases potency up to 47%) or vitamin 
C or D [37-39]. In recent years, radiofrequency devices 
have been used to treat telangiectasia, but thus far, results 
are not promising, with radiofrequency tending to be 
overrated as a good-for-everything technique [40]. 
Recently, Botox has been introduced as a therapeutic 
method in the treatment of rosacea: it seems its actions take 
place through the nervous system by lowering local 
vascularity, but the mode of action and efficacy are yet to 
be fully evaluated [41]. 
The factors that lead to the appearance of rosacea are 
not fully elucidated. Some innate or acquired immune 
dysfunctions are often associated with several 
neurovascular dysfunctions, with a genetic component 
underlying the appearance of rosacea [42]. These 
dysfunctions are directly or indirectly associated Demodex 
Folliculorum (DF) (through its own bacteria 
endosymbiosis, or other bacteria unrelated to DF such as 
Staphylococcus), epidermidis, ultraviolet (UV) radiation, 
extreme temperatures, stress, congestive foods, and the 
presence of metabolic syndrome or diabetes mellitus [38-
41]. DF has been shown to have Bacillus bacteria 
endosymbionts such as Bacillus Oleronius, Bacillus 
Pumilus, Bacilus simplex, Cereus or Corynebacterium 
kroppenstedtii [44-46]. 
DF, either directly or through its endosymbionts, can 
trigger the cascade of immunologically active peptides by 
interacting directly or indirectly with various structures, 
including receiver type. It has also been found that some 
skin receptors exhibit enhanced receptivity, such as Toll-
like receptor (TLR) 2, nucleotide-binding oligomerization 
domain (NOD)-like receptor, and transient vanilloid 
receptor potential (TRPV4). Activation of these receptors 
causes the production of immune peptides (eg, LL-37) and 
various cytokines and chemokines, which induce a variety 
of inflammatory reactions [47]. The TLR2 receptor can 
also activate kappa B nuclear transcription factor (NF-kB), 
further accentuating inflammation [48]. Implicitly, they 
will also cause neurovascular changes. Mast cells also 
participate in the appearance of rosacea by increasing 
inflammation, angiogenesis, and fibrosis [49]. More 
recently, rosacea and other skin diseases such as psoriasis 
and atopic dermatitis have been linked to intestinal 
dysbiosis, although the role of the association of 
NDYAG laser combined with pulsed light in the treatment of rosacea 
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Helicobacter pylori infection or SIBO-small intestinal 
bacterial overgrowth is still debated [50]. However, the 
cascade of inflammatory reactions and triggers is much 
wider. Thus, keratinocytes will release cathelicidin, 
vascular endothelial growth factor and endothelin-1, 
endothelial cells will release nitric oxide, mast cells will 
release cathelicidin and matrix metalloproteinases, 
macrophages will release interferon-gamma, tumor 
necrosis factor, matrix metalloproteinase and interleukin-
26 and in addition, all these factors can communicate 
directly with the cutaneous nervous system through active 
neurovascular neuropeptides. The consequences of these 
many pathophysiological changes over the long term are: 
vasodilation, glandular hyperplasia, and fibrosis.  The 
presence of rosacea may contraindicate or limit the 
indications for some dermato-cosmetic treatments such as 
chemical peels or hyaluronic acid treatments [51-53]. It 
may also limit the use of other types of lasers for various 
dermatological conditions that induce local vasodilation; in 
these cases, the order of treatment must be analyzed [54-
55]. 
Conclusions 
Rosacea is a dermatological condition with 
multifactorial etiology. Its clinical forms require complex 
treatments on the one hand, combined, both topical and 
systemic but also by using NdYag laser devices and intense 
pulsed light; on the other hand, the treatments are adapted 
to the particularities and comorbidities associated with 
rosacea in our patients.  
This paper presents the results of the treatments 
performed, with the help of a Cutera Xeo laser, using 2 
probes: NdYag 1064 nm and LimeLight 520-1100 nm, 
with a window of 10x30 mm. The maximum number of 
sessions was 6, the minimum was 3. Most treatments were 
made without anesthetic cream though some patients 
wanted anesthetic cream. The degree of discomfort during 
the procedure was medium, and treatments were started 
from energies of 14-15 J / cm2 and increased progressively, 
from session to session, to energies of 18-19 J / cm2. The 
average recovery time was 5 days, during which the patient 
presented severe edema. As side effects, there were small 
bruises, small pustules, burning sensation, and transient 
stinging. As complications there were registered, in 3 
patients, areas of hyperpigmentation which partially 
remitted. We did not observe post-procedure scars. 
Rosacea treatment remains to be individualized according 
to the needs and status of patients.  
Conflict of interest disclosure 
There are no known conflicts of interest in the 
publication of this article. The manuscript was read and 
approved by all authors. 
Compliance with ethical standards 
Any aspect of the work covered in this manuscript has 
been conducted with the ethical approval of all relevant 
bodies and that such approvals are acknowledged within 
the manuscript.  
References 
1. Yuan X, Huang X, Wang B, et al. Relationship 
between rosacea and dietary factors: A multicenter 
retrospective case-control survey. J Dermatol. 
2019;46(3):219-225. doi:10.1111/1346-8138.14771  
2. Plewig G, Kligman AM. History of Acne and 
Rosacea. Acne And Rosacea. Berlin: Springer; 2000. 
https://www.springer.com/gp/book/9783642640964 
3. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang 
S, Chien AL. Rosacea is associated with chronic 
systemic diseases in a skin severity-dependent 
manner: results of a case-control study. J  
Am Acad Dermatol. 2015;73(4):604-608. doi: 
10.1016/j.jaad.2015.07.009. 
4. Parisi R, Yiu ZZN. The worldwide epidemiology of 
rosacea. Br J Dermatol. 2018;179(2):239-240. 
doi:10.1111/bjd.16788 
5. Gether L, Overgaard LK, Egeberg A, Thyssen JP. 
Incidence and prevalence of rosacea: a systematic 
review and meta-analysis. Br J Dermatol. 
2018;179(2):282-289. doi:10.1111/bjd.16481 
6. Gallo RL, Granstein RD, Kang S, et al. Standard 
classification and pathophysiology of rosacea: The 
2017 update by the National Rosacea Society Expert 
Committee. J Am Acad Dermatol. 2018;78(1):148-
155. doi:10.1016/j.jaad.2017.08.037 
7. Engin B, Özkoca D, Kutlubay Z, Serdaroğlu S. 
Conventional and Novel Treatment Modalities in 
Rosacea. Clin Cosmet Investig Dermatol. 
2020;13:179-186. Published 2020 Feb 20. 
doi:10.2147/CCID.S194074. 
8. Tuta LA, Iorga I, Azis O, Voinea F. End-of-life Care 
in Erderly Patients with End-Stage Renal Disease – 
Ethical and Clinical Issues. SGEM 2015, Book 1: 
Psychology and Psyhiatry, Sociology and Healthcare, 
Education Conference Proceedings. 2015;1:487-493. 
9. Tatu AL, Cristea VC. Pityriasis Folliculorum of the 
Back Thoracic Area: Pityrosporum, Keratin Plugs, or 
Demodex Involved?. J Cutan Med Surg. 2017; 
21(5):441. doi:10.1177/1203475417711114 
10. Tatu AL, Cristea VC. Unilateral Blepharitis With 
Fine Follicular Scaling. J Cutan Med Surg. 2017; 
21(5):442. doi:10.1177/1203475417711124 
11. Tatu AL. Umbilicated Blue-Black Lesion on the 
Lateral Thorax. J Cutan Med Surg. 2017; 21(3):252. 
doi:10.1177/1203475417694859 
Valeriu Ardeleanu et al.  
 210 
12. Tatu AL, Clatici VG, Nwabudike LC. Rosacea-like 
demodicosis (but not primary demodicosis) and 
papulopustular rosacea may be two phenotypes of the 
same disease - a microbioma, therapeutic and 
diagnostic tools perspective. J Eur Acad Dermatol 
Venereol. 2019;33(1):e46-e47. doi:10.1111/jdv.15166 
13. Tan J, Almeida LM, Bewley A, et al. Updating the 
diagnosis, classification and assessment of rosacea: 
recommendations from the global ROSacea 
COnsensus (ROSCO) panel. Br J Dermatol. 
2017;176(2):431-438. doi:10.1111/bjd.15122. 
14. Tatu AL. Topical Steroid Induced Facial Rosaceiform 
Dermatitis. Acta Endocrinol (Buchar). 2016;12(2):232-
233. doi:10.4183/aeb.2016.232 
15. Tatu AL, Ionescu MA, Clatici VG, Cristea VC. 
Bacillus cereus strain isolated from Demodex 
folliculorum in patients with topical steroid-induced 
rosaceiform facial dermatitis. An  
Bras Dermatol. 2016; 91(5): 676-678. doi: 
10.1590/abd1806-4841.20165214   
16. Tatu AL, Clătici V. Some correlations between the 
clinical and dermoscopic features of steroid induced 
facial dermatitis. J Am Acad Dermatol. 2015; 
72(5)Suppl 1:AB91. 
17. Tatu AL, Ionescu MA, Nwabudike LC. Contact Allergy 
to Topical Mometasone Furoate Confirmed by 
Rechallenge and Patch Test. Am J Ther. 2018;25(4):e497-
e498. doi:10.1097/MJT.0000000000000581 
18. Baldwin HE, Harper J, Baradaran S, Patel V. 
Erythema of Rosacea Affects Health-Related Quality 
of Life: Results of a Survey Conducted in 
Collaboration with the National Rosacea Society. 
Dermatol Ther (Heidelb). 2019;9(4):725-734. 
doi:10.1007/s13555-019-00322-5. 
19. Tofolean DE, Mazilu L, Stăniceanu F, et al. Clinical 
presentation of a patient with cutis laxa with systemic 
involvement: a case report. Rom J Morphol Embryol. 
2015;56(3):1205-1210. 
20. Di Nardo A, Holmes AD, Muto Y, et al. Improved 
clinical outcome and biomarkers in adults with 
papulopustular rosacea treated with doxycycline 
modified-release capsules in a randomized trial. J Am 
Acad Dermatol. 2016;74(6):1086-1092. doi: 
10.1016/j.jaad.2016.01.023. 
21. Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman 
SR. New developments in the treatment of rosacea - 
role of once-daily ivermectin cream. Clin Cosmet 
Investig Dermatol. 2016; 9: 71-77. doi: 
10.2147/CCID.S98091. 
22. Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: 
Molecular Mechanisms and Management of a 
Chronic Cutaneous Inflammatory Condition. Int J 
Mol Sci. 2016;17(9):1562. Published 2016 Sep 15. 
doi:10.3390/ijms17091562. 
23. Del Rosso JQ. Evaluating the role of topical therapies 
in the management of rosacea: focus on combination 
sodium sulfacetamide and sulfur formulations. Cutis. 
2004;73(1 Suppl):29-33. 
24. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. 
Topical and systemic therapies in the treatment of 
rosacea. J Am Acad Dermatol. 2015;72(5):761-772. 
doi:10.1016/j.jaad.2014.08.027  
25. Anzengruber F, Czernielewski J, Conrad C, et al. 
Swiss S1 guideline for the treatment of rosacea. J Eur 
Acad Dermatol Venereol. 2017;31(11):1775-1791. 
doi:10.1111/jdv.14349.  
26. Motofei IG, Rowland DL, Baconi DL, et al. 
Androgenetic alopecia; drug safety and therapeutic 
strategies. Expert Opin Drug Saf. 2018;17(4):407-
412. doi:10.1080/14740338.2018.1430765  
27. Two AM, Hata TR, Nakatsuji T, et al. Reduction in 
serine protease activity correlates with improved 
rosacea severity in a small, randomized pilot study of 
a topical serine protease inhibitor. J Invest Dermatol. 
2014;134(4):1143-1145. doi:10.1038/jid.2013.472. 
28. Li X, Guo H, Tian Q, et al. Effects of 5-
aminolevulinic acid-mediated photodynamic therapy 
on antibiotic-resistant staphylococcal biofilm: an in 
vitro study. J Surg Res. 2013;184(2):1013-1021. 
doi:10.1016/j.jss.2013.03.094.  
29. Cecic I, Sun J, Korbelik M. Role of complement 
anaphylatoxin C3a in photodynamic therapy-elicited 
engagement of host neutrophils and other immune 
cells. Photochem Photobiol. 2006;82(2): 558-562. 
doi:10.1562/2005-09-09-RA-681. 
30. Lee JB, Bae SH, Moon KR, Na EY, Yun SJ, Lee SC. 
Light-emitting diodes downregulate cathelicidin, 
kallikrein and toll-like receptor 2 expressions in 
keratinocytes and rosacea-like mouse skin. Exp 
Dermatol. 2016;25(12):956-961. doi:10.1111/exd.13133 
31. Noborio R, Nishida E, Kurokawa M, Morita A. A 
new targeted blue light phototherapy for the treatment 
of acne. Photodermatol Photoimmunol  
Photomed. 2007; 23(1): 32-34. doi: 10.1111/j.1600-
0781.2007.00268.x 
32. Kumar A, Ghate V, Kim MJ, Zhou W, Khoo GH, Yuk 
HG. Antibacterial efficacy of 405, 460 and 520 nm 
light emitting diodes on Lactobacillus plantarum, 
Staphylococcus aureus and Vibrio parahaemolyticus. 
J Appl Microbiol. 2016; 120(1):49-56. doi: 
10.1111/jam.12975. 
33. Sorbellini E, De Padova MP, Rinaldi F. Coupled blue 
and red light-emitting diodes therapy efficacy in 
patients with rosacea: two case reports. J Med Case 
Rep. 2020;14(1):22. Published 2020 Jan 28. 
doi:10.1186/s13256-019-2339-6. 
34. Handler MZ, Bloom BS, Goldberg DJ. IPL vs PDL in 
treatment of facial erythema: A split-face study. J 
NDYAG laser combined with pulsed light in the treatment of rosacea 
 211 
Cosmet Dermatol. 2017; 16(4): 450-453. doi: 
10.1111/jocd.12365 
35. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong 
CK. Botulinum toxin for the treatment of refractory 
erythema and flushing of rosacea. Dermatology. 
2015;230(4):299-301. doi:10.1159/000368773 
36. Feaster B, Cline A, Feldman SR, Taylor S. Clinical 
effectiveness of novel rosacea therapies. Curr Opin 
Pharmacol. 2019;46:14-18. 
37. Maxwell EL, Ellis DA, Manis H. Acne rosacea: 
effectiveness of 532 nm laser on the cosmetic 
appearance of the skin. J Otolaryngol Head Neck 
Surg. 2010;39(3):292-296. 
38. Stanescu AMA, Grajdeanu IV, Iancu MA, et al. 
Correlation of Oral Vitamin D Administration with 
the Severity of Psoriasis and the Presence of 
Metabolic Syndrome. REVISTA DE CHIMIE. 2018; 
69(7):1668-72. 
39. Stoian Pantea A, Bala C, Rusu A, et al. Gender 
Differences in the Association of Ferritin and 25-
hydroxyvitamin D. REVISTA DE CHIMIE 2018; 
69(4):864-869.  
40. Kim SJ, Lee Y, Seo YJ, Lee JH, Im M. Comparative 
Efficacy of Radiofrequency and Pulsed Dye Laser in 
the Treatment of Rosacea. Dermatol Surg. 
2017;43(2):204-209. 
doi:10.1097/DSS.0000000000000968 
41. Scala J, Vojvodic A, Vojvodic P, et al. Botulin Toxin 
Use in Rosacea and Facial Flushing Treatment. Open 
Access Maced J Med Sci. 2019;7(18):2985-2987. 
doi:10.3889/oamjms.2019.784  
42. Holmes AD, Steinhoff M. Integrative concepts of 
rosacea pathophysiology, clinical presentation and 
new therapeutics. Exp Dermatol. 2017;26(8):659-
667. doi:10.1111/exd.13143 
43. Tatu AL, Clatici V, Cristea V. Isolation of Bacillus 
simplex strain from Demodex folliculorum and 
observations about Demodicosis spinulosa. Clin Exp 
Dermatol. 2016;41(7):818-820. doi:10.1111/ced.12893 
44. Tatu AL, Ionescu MA, Cristea VC. Demodex 
folliculorum associated Bacillus pumilus in lesional 
areas in rosacea. Indian J Dermatol Venereol Leprol. 
2017;83(5):610-611. 
doi:10.4103/ijdvl.IJDVL_921_16. 
45. Tatu AL, Nwabudike LC. Reply to: Kubiak K et al. 
Endosymbiosis and its significance in dermatology. J 
Eur Acad Dermatol Venereol. 2018;32(9):e346-e347. 
doi:10.1111/jdv.14921 
46. Clanner-Engelshofen BM, French LE, Reinholz M. 
Corynebacterium kroppenstedtii subsp. demodicis is 
the endobacterium of Demodex folliculorum. J Eur 
Acad Dermatol Venereol. 2020;34(5):1043-1049. 
doi:10.1111/jdv.16069 
47. Ardeleanu V, Dobre M, Georgescu EM. Deep Facial 
Wrinkle Treatment Outcome After First Injection of 
Reticulated Hyaluronic Acid. Rev Chim. 2015; 
66(12):2129-2131. 
48. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 
expression is increased in rosacea and stimulates 
enhanced serine protease production by 
keratinocytes. J Invest Dermatol. 2011;131(3):688-
697. doi:10.1038/jid.2010.351 
49. Merlo EM. Adolescent phobia as a “mask object”. 
Mediterranean Journal of Clinical Psychology. 
2019;7(1). doi:10.6092/2282-1619/2019.7.2241 
50. Wang L, Wang YJ, Hao D, et al. The Theranostics 
Role of Mast Cells in the Pathophysiology of 
Rosacea. Front Med (Lausanne). 2020;6:324. 
doi:10.3389/fmed.2019.00324 
51. Ardeleanu V, Berbece SI, Florescu IP, Jecan RC. The 
Use of Hyaluronic Acid Combined with Teosyal 
Redensity II for the Treatment of Dark Circles Under 
the Eyes. Materiale Plastice.  2017;54(1):37-40. 
52. Vaughn AR, Notay M, Clark AK, Sivamani RK. 
Skin-gut axis: The relationship between intestinal 
bacteria and skin health. World J Dermatol. 2017; 
6(4):52–58. doi:10.5314/wjd.v6.i4.52 
53. Jecan RC,  Nicolau A, Florescu IP, Ardeleanu V, 
Berbece S. Use of Trichloroacetic Acid in Treating 
Facial Hyperpigmentation. Materiale Plastice. 2017; 
54(1):88-90. 
54. Ardeleanu V, Sabina Radaschin D, Tatu AL. Excimer 
laser for psoriasis treatment: A case report and short 
review. Exp Ther Med. 2020;20(1):52-55. doi: 
10.3892/etm.2020.8529. 
55. Tatu AL, Radaschin DS, Constantin VD, Stana P, 
Ardeleanu V. Laser therapy in superficial morphea 
lesions - indications, limitations and therapeutic 
alternatives. J Mind Med Sci. 2020;7(1):46-51. 
doi:10.22543/7674.71.P4651 
 
 
 
 
 
 
 
 
 
 
 
